Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC)

Clinical and Translational Oncology

Volumn 10, Issue 4, 2008, Pages 198-203

  Costa, Enric Carcereny ^a   Segarra, Núria Viñolas ^a   Vilaplana, Pere Gascón ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Angiogenesis; Inhibitors; Non small cell lung cancer; Treatment

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; AGO 13676; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; INTERFERON; INTERLEUKIN 2; MOTESANIB; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTRIPIN TRAP; VATALANIB; ZK 22854;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; QT PROLONGATION; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; LUNG TUMOR; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 51649130050     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-008-0182-0     Document Type: Review

References (32)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer Statistics 2007. CA Cancer J Clin 57:43-66
2. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123-132
4. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
5. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027
6. Woolard J, Wang WY, Bevan HS et al (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64:7822-7835
7. Toi M, Matsumonto T, Bando H et al (2001) Vascular endothelial growth factor: Its prognostic, predictive and therapeutic implications. Lancet Oncol 2:667-673
8. Maillauer B, Longhi MP, Plate KH et al (1996) Dominant negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56:1615-1620
9. Jain R (2005) Normalisation of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62
10. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluoracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
11. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799
12. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
13. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22:2184-2191
14. Sandler AB, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542-2550
15. Manegold C, von Pawel J, Zatloukal P et al (2007) Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25[Suppl 18]:LBA7514
16. Ciardeieillo F, Troiani T, Bianco R et al (2006) Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: A rational approach for multitargeted anticancer therapy. Ann Oncol 17:109-114
17. Herbst RS, Johnson DH, Mininberg E et al (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555
18. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
19. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
20. Gatzemeier U, Blumenschein G, Fosella F et al (2006) Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24[Suppl 18]:7002
21. Abrams TJ, Lee LB, Murray LJ et al (2003) SU11248 inhibits kit and platelet-derived growth factor receptor in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
22. Socinski MA, Novello S, Brahmer JR et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656
23. Wood JM, Bold G, Buchdunger E et al (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189
24. Thomas AL, Morgan B, Horsfield MA (2005) A phase I study of the safety, tolerability pharmacokinetics and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23:4162-4171
25. Wedge SR, Ogilvie DJ, Dukes M et al (2002) ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655
26. Holden SN, Eckhardt SG, Basser R et al (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signalling, in patients with solid, malignant tumors. Ann Oncol 16:1391-1397
27. Huang J, Frischer JS, Serur A et al (2003) Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 100:7785-7790
28. Jackson E, Esparza-Coss E, Bankson JA et al (2005) The effect of AMG 706, a novel kinase inhibitor on vascular permeability and blood flow as assessed by dynamic contrast enhanced magnetic resonance imaging in an in vivo preclinical tumor model. J Clin Oncol 23:225S
29. Beebe JS, Jani JP, Knauth E et al (2003) Pharmacological characterization of CP 547,632, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 63:7301-7309
30. Cohen RB, Simon G, Langer CJ et al (2004) Phase I trial of oral CP 547,32 (VEGFR2) in combination with paclitaxel and carboplatin in advanced non small cell lung cancer (NSCLC). J Clin Oncol 22:14S
31. Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: A highly potent, orally biovailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400
32. Lee SM, Rudd PJ, Gower RM et al (2007) A phase II randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2(8):S359